Alex Adjei
The Cleveland Clinic · Mayo Clinic · Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alex Adjei as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:03 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03647163 · Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsVyriad, Inc. · active not recruiting · Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma · principal investigator
- Ph1NCT03455556 · Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung CancerMayo Clinic · terminated · Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7 · principal investigator
- Ph1NCT03237390 · Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsMayo Clinic · completed · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT02483858 · Study of Oral PQR309 in Patients With Advanced Solid TumorsPIQUR Therapeutics AG · completed · Cancer · principal investigator
- Ph1NCT02033148 · Icotinib Hydrochloride in Treating Patients With Advanced CancersRoswell Park Cancer Institute · withdrawn · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT01971489 · Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid TumorsRoswell Park Cancer Institute · withdrawn · Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT01540253 · PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or MetastaticRoswell Park Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT01527136 · Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By SurgeryRoswell Park Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1/Ph2NCT01188499 · Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid TumorsTetraLogic Pharmaceuticals · completed · Cancer · principal investigator
- Ph1NCT01159301 · Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaNational Cancer Institute (NCI) · terminated · Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) · principal investigator
- Ph1NCT00993239 · Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or LymphomaTetraLogic Pharmaceuticals · completed · Cancer · principal investigator
- Ph2NCT00750698 · A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibSyndax Pharmaceuticals · terminated · Non Small Cell Lung Cancer · study chair
- Ph3NCT00738881 · Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerNational Cancer Institute (NCI) · terminated · Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT00098540 · Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT00093756 · Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00079235 · CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00055757 · Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00052949 · Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Recurrent Small Cell Lung Cancer · principal investigator
- Ph1NCT00028587 · PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Experimental Therapeutics ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2022 · $98,369 awarded in 2022Same name and institution; not confirmed by an ID
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2016 to 2019 · $667,474 awarded in 2019Same name and institution; not confirmed by an ID
- Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.U10CA180866 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2014 to 2015 · $523,600 awarded in 2015Same name and institution; not confirmed by an ID
- Protocol-Specific Research SupportP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2007 to 2012 · $271,183 awarded in 2012Same name and institution; not confirmed by an ID
- EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ZD1839M01RR000585 · NCRR · MAYO CLINIC ROCHESTER · fiscal years 1999 to 2005 · $12,321 awarded in 2005Same name and institution; not confirmed by an ID
- Phase I Clinical Trials of Anticancer AgentsU01CA069912 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2003 to 2005 · $670,900 awarded in 2005Same name and institution; not confirmed by an ID
- CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORSK01CA077112 · NCI · MAYO CLINIC ROCHESTER · fiscal years 1997 to 2001 · $145,313 awarded in 2001Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT00738881
- North Central Cancer Treatment GroupU10CA025224 · NCI · MAYO CLINIC ROCHESTER · PI JAN C BUCKNER · fiscal years 1985 to 2013
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:03 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol · 2004515 citationsRCR 9.3
- A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.Clin Cancer Res · 2003375 citationsRCR 6.4
- A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.Cancer Res · 2000229 citationsRCR 4.2
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.J Clin Oncol · 2003165 citationsRCR 2.6
- Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol · 2017141 citationsRCR 4.2
- Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.J Immunother Cancer · 2022138 citationsRCR 7.9
- Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.J Clin Oncol · 2006115 citationsRCR 2.3
- A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.Mol Cancer Ther · 2015113 citationsRCR 3.1
- Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.J Clin Oncol · 2000104 citationsRCR 2.6
- Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.J Thorac Oncol · 202393 citationsRCR 6.5